| |
Basal-like xenograft (MAS98.12)
|
Luminal-like xenograft (MAS98.06)
|
|---|
| |
Primary tumor
|
Xenograft
|
Primary tumor
|
Xenograft
|
|---|
|
Tumor grade
|
Grade III IDC
|
NA
|
Grade III IDC
|
NA
|
|
Lymph node status
|
No metastasis
|
NA
|
Metastasis to 12 of 25 nodes
|
NA
|
| | | |
No distant metastases
| |
|
Differentiation
|
Poorly differentiated
|
Poorly differentiated
|
Well differentiated
|
Poorly differentiated
|
|
Hormone receptor status
|
ER-/PgR+**
|
ER-/PgR-
|
ER+/PgR+
|
ER+/PgR+
|
|
ERBB2 amplification*
|
Negative
|
Negative
|
Negative
|
Negative
|
|
Intrinsic molecular subtype
|
Basal-like
|
Basal-like
|
Luminal-like
|
Luminal-like
|
|
TP53 status
|
Wildtype
|
Mutated
|
Mutated
|
Mutated
|
|
Volume doubling time
|
NA
|
1-2 days
|
NA
|
7 days
|
|
Proliferation index (Ki67)
|
Missing
|
28%
|
Missing
|
35%
|
- Summary of characteristics related to genotype and phenotype of the xenograft models
- * Measured at the DNA level by array Comparative Genomic Hybridization (aCGH)
- ** The primary basal-like carcinoma had very weak cytoplasmic staining for PgR29.
